$KIDS

Pritzker Jennifer N. sold $7.8M of KIDS (indirect holdings)

Pritzker Jennifer N. sold 336,831 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01.

Original reporting
SEC EDGAR · Pritzker Jennifer N.
Published Sep 1, 2026, 10:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KIDS
Bearish
medium confidence
Mentioned
$KIDS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSBearishMed
01

Why it matters

The $7.8M sale represents a notable reduction in a 10% owner's stake, possibly prompting short interest.

02

Market read

Direct relevance to KIDS stock; limited spillover to peers.

03

What to watch

Potential tax planning or liquidity needs unrelated to business outlook.

Relevance 6/10Novelty 6/10Timing: post‑market filing on Sep 1 2026

Background

Form 4 filing discloses insider transactions; investors monitor large sales for signals.

Company-level read

Ticker impact

$KIDSBearishMedium confidence
Context

Jennifer Pritzker sold 336,831 shares for $7.8M, reducing her stake to 6.5M shares.

Expected impact

Potential short-term downside of 2‑4% as market digests the sale.

Evidence & confidence

10% owner exiting a multi‑million‑dollar position is material; no other catalyst present.

Market effects

Minimal impact on orthopedics sector; insider sell is company‑specific.

U.S. market only; no broader regional effect.

Low; limited to KIDS shareholders.

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Jennifer N. Pritzker

    10% owner of Orthopedics Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.